The development of technologies that allow the detection of circulating tumor cells, cell free DNA, or exosomes, combined with the advancements of sequencing technologies and the identification of novel biomarkers now allow more accurate detection and possible insights into the characteristics of malignant tumors than traditional biopsies (e.g. immunohistochemistry pathology type tests and/or tumor marker immunoassays). Liquid biopsy enables the detection of circulating tumor DNA in healthy individuals that are at high risk for cancer, the monitoring of patients with active or previously diagnosed cancer for risk of recurrence, or the detection of a molecular target or marker that may be indicative of a high probability of response to a specific treatment. This dynamic field is undergoing significant growth with many new startups and major companies commercializing and offering liquid biopsy products and services to the market.

At the 10th Personalized Medicine World Conference (PMWC) Silicon Valley on January 24-27, we have four sessions dedicated to liquid biopsy: Liquid Biopsy – A Game Changer, Non-Invasive Liquid Biopsies for Cancer Patients, Commercial Applications in Liquid Biopsyand Liquid Biopsy: The Right Tool for the Right JobThis is a great opportunity to delve into this evolving field, learn first-hand the latest advancements, meet the opinion leaders and companies actively developing and commercializing products in the space, and hear about successful applications that will shape the evolution of healthcare.


  • Frederic Pla, Ph.D., Chief Business & Product Dev. Officer, Genomic Health
  • Thomas Krahn, Ph.D., Head of Global Biomarker Research, Bayer
  • Nicholas Dracopoli, Ph.D., VP, Head Oncology Biomarkers, Janssen R&D
  • Phil Stephens, Ph.D., Chief Scientific Officer, Foundation Medicine
  • Helmy Eltoukhy, Ph.D., CEO Guardant Health
  • Murali Prahalad, Pd.D., President & CEO, Epic Sciences
  • Victor E. Velculescu, M.D., Ph.D., Dir., Johns Hopkins Kimmel Cancer Center
  • Raghu Kalluri, M.D., Ph.D., Chair & Professor, Cancer Biology, MD Anderson
  • Walter Koch, Ph.D., VP & Head Of Global Research, Roche Molecular
  • Maximilian Diehn, M.D., Ph.D., Assistant Professor, Stanford University
  • Katherine Richardson, Ph.D., VP, Research & Development, Transgenomic
  • Matthew Hill, Ph.D., Vice President, Research & Development, Natera
  • Wolfgang Daum, Chairman and CEO, Toma Biosciences
  • Michael Nall, President and CEO, Biocept
  • Mark Erlander, Ph.D., CSO, Trovagene
  • Jean-Francois Laes, Ph.D., CTO, ONCODNA
  • Paul Song, M.D., CMO, Cynvenio
  • David Spetzler, Ph.D., SVP and CSO, Caris Life Sciences
  • Roopom Banerjee, President and CEO, Raindance Technologies
  • George Karlin-Neumann, Ph.D., Director of Scientific Affairs, Bio-Rad